NO974453L - Proteinkinase C-hemmere - Google Patents
Proteinkinase C-hemmereInfo
- Publication number
- NO974453L NO974453L NO974453A NO974453A NO974453L NO 974453 L NO974453 L NO 974453L NO 974453 A NO974453 A NO 974453A NO 974453 A NO974453 A NO 974453A NO 974453 L NO974453 L NO 974453L
- Authority
- NO
- Norway
- Prior art keywords
- inhibitors
- protein kinase
- kinase
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/17—Unsaturated ethers containing halogen
- C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
- C07C43/1745—Unsaturated ethers containing halogen containing six-membered aromatic rings having more than one ether bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
- C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/413,735 US5624949A (en) | 1993-12-07 | 1995-03-30 | Protein kinase C inhibitors |
PCT/US1996/004245 WO1996030048A1 (en) | 1995-03-30 | 1996-03-28 | Protein kinase c inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
NO974453D0 NO974453D0 (no) | 1997-09-26 |
NO974453L true NO974453L (no) | 1997-11-19 |
NO309271B1 NO309271B1 (no) | 2001-01-08 |
Family
ID=23638401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO974453A NO309271B1 (no) | 1995-03-30 | 1997-09-26 | Proteinkinase C-hemmere, farmasöytisk formulering inneholdende slike hemmere, anvendelse derav, fremgangsmåte for deres fremstilling, og mellomprodukt |
Country Status (16)
Country | Link |
---|---|
US (10) | US5624949A (no) |
EP (1) | EP0735038A1 (no) |
JP (1) | JPH11507327A (no) |
KR (1) | KR100319945B1 (no) |
CN (1) | CN1093767C (no) |
AU (1) | AU701988B2 (no) |
CA (1) | CA2216535C (no) |
CZ (1) | CZ286301B6 (no) |
EA (1) | EA000598B1 (no) |
HU (1) | HUP9801250A3 (no) |
MX (1) | MX9707431A (no) |
NO (1) | NO309271B1 (no) |
NZ (1) | NZ305276A (no) |
PL (1) | PL183600B1 (no) |
TR (1) | TR199701073T1 (no) |
WO (1) | WO1996030048A1 (no) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9404831A (pt) * | 1993-12-07 | 1995-08-08 | Lilly Co Eli | Composto,formulação farmacêutica e processo de preparação de um composto |
US5723456A (en) * | 1993-12-07 | 1998-03-03 | Eli Lilly & Company | Therapeutic treatment for cardiovascular diseases |
US5843935A (en) * | 1993-12-07 | 1998-12-01 | Eli Lilly And Company | Protein kinase C inhibitors |
DE69600784T2 (de) * | 1995-11-20 | 1999-04-08 | Lilly Co Eli | Proteinkinase-C-Inhibitor |
PL184728B1 (pl) * | 1995-11-20 | 2002-12-31 | Lilly Co Eli | Nowe pochodne bisindolilomaleimidu z mostkiem N,N'i środek farmaceutyczny |
US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
UA54427C2 (uk) * | 1996-05-01 | 2003-03-17 | Елі Ліллі Енд Компані | Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту |
AU703395B2 (en) * | 1996-05-01 | 1999-03-25 | Eli Lilly And Company | Halo-substituted protein kinase C inhibitors |
KR20000065171A (ko) * | 1996-05-01 | 2000-11-06 | 피터 지. 스트링거 | 혈관내피세포성장인자관련질병의치료방법 |
US6093709A (en) * | 1996-08-22 | 2000-07-25 | Eli Lilly And Company | Therapeutic treatment for sexual dysfunctions |
CN1228082A (zh) * | 1996-08-23 | 1999-09-08 | 伊莱利利公司 | 双吲哚基马来酰亚胺的合成 |
US5962446A (en) * | 1996-08-30 | 1999-10-05 | Eli Lilly And Company | Therapetutic treatment for human T cell lymphotrophic virus type 1 infection |
US6107327A (en) * | 1996-08-30 | 2000-08-22 | Eli Lilly And Company | Therapeutic treatment for HIV infection |
US6040152A (en) * | 1996-12-31 | 2000-03-21 | National Jewish Medical And Research Center | Method and assay for regulation of T cell proliferation |
US6093740A (en) * | 1997-04-30 | 2000-07-25 | Eli Lilly And Company | Therapeutic treatment for skin disorders |
JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
WO1999026609A2 (en) * | 1997-11-26 | 1999-06-03 | Eli Lilly And Company | Therapeutic treatment for chronic myeloid leukemia and acute lymphoid leukemia |
CA2227688C (en) | 1998-01-16 | 2007-07-31 | James W. Critchfield | Methods and compositions for inhibition of viral replication |
US6291446B1 (en) * | 1998-03-05 | 2001-09-18 | Eli Lilly And Company | Therapeutic treatment for cytomegalovirus infection |
US6225301B1 (en) | 1998-03-05 | 2001-05-01 | Eli Lilly And Company | Therapeutic treatment for renal dysfunction |
US6103713A (en) * | 1998-03-05 | 2000-08-15 | Eli Lilly And Company | Therapeutic treatment for autoimmune diseases |
US6103712A (en) * | 1998-03-05 | 2000-08-15 | Eli Lilly And Company | Therapeutic treatment for asthma |
ATE251624T1 (de) * | 1998-03-13 | 2003-10-15 | Univ British Columbia | Granulatimide-derivate zur behandlung von krebs |
CA2245029A1 (en) | 1998-03-13 | 1999-09-13 | University Of British Columbia | Granulatimide compounds as g2 checkpoint inhibitors |
US6127401A (en) | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
US6013646A (en) | 1998-07-02 | 2000-01-11 | Bayer Corporation | Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer |
US6841567B1 (en) | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
US6284783B1 (en) | 1999-06-09 | 2001-09-04 | The Uab Research Foundation | Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis |
US6399780B1 (en) * | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
US6852688B2 (en) | 2000-03-10 | 2005-02-08 | University Of Florida | Compositions for treating diabetic retinopathy and methods of using same |
US7297762B2 (en) * | 2000-04-24 | 2007-11-20 | Yale University | Modified avian pancreatic polypeptide miniature binding proteins |
US20020048581A1 (en) * | 2000-07-18 | 2002-04-25 | King George L. | Modulation of nitric oxide synthase by PKC |
US7425537B2 (en) | 2000-08-22 | 2008-09-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | SH2 domain binding inhibitors |
JP2004526676A (ja) | 2000-12-08 | 2004-09-02 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | キナーゼ阻害剤として有用な大員複素環式化合物 |
DK1362047T3 (da) | 2000-12-08 | 2006-09-04 | Ortho Mcneil Pharm Inc | Indazolylsubstituerede pyrrolinforbindelser som kinaseinhibitorer |
DE10109280A1 (de) * | 2001-02-26 | 2002-09-05 | Peter Mayser | Indolderivate mit inhibitorischer Wirkung auf Proteinkinasen |
US6559299B2 (en) * | 2001-03-29 | 2003-05-06 | Merck & Co., Inc. | Preparation and isolation of indolocarbazole glycosides |
GB0125659D0 (en) * | 2001-10-25 | 2001-12-19 | Ssl Int Plc | Spermicides |
GB0125658D0 (en) * | 2001-10-25 | 2001-12-19 | Ssl Int Plc | Medicaments |
WO2003059372A2 (en) * | 2001-12-29 | 2003-07-24 | Novo Nordisk A/S | Combined use of a glp-1 compound and a modulator of diabetic late complications |
EP1501511A4 (en) * | 2002-05-06 | 2006-06-07 | Univ Washington | METHODS OF TREATING GLAUCOMA AND OTHER CONDITIONS INDUCED BY EXPRESSION OF NOS-2 BY INHIBITING THE EGFR PATHWAY |
BR0311821A (pt) | 2002-06-05 | 2005-04-05 | Janssen Pharmaceutica Nv | Derivados de bisindolil-maleimid como inibidores de cinase |
CA2488798A1 (en) * | 2002-06-05 | 2003-12-18 | Janssen Pharmaceutica N.V. | Substituted pyrrolines as kinase inhibitors |
CA2393720C (en) * | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
US20040175384A1 (en) * | 2003-12-12 | 2004-09-09 | Mohapatra Shyam S. | Protein kinase C as a target for the treatment of respiratory syncytial virus |
WO2005000836A1 (en) * | 2003-06-13 | 2005-01-06 | Janssen Pharmaceutica N.V. | Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors |
EP1633774B1 (en) | 2003-06-18 | 2010-02-17 | Tranzyme Pharma Inc. | Macrocyclic antagonists of the motilin receptor |
CA2526284C (en) | 2003-06-25 | 2014-11-18 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
KR101206206B1 (ko) * | 2003-07-22 | 2012-11-29 | 크루셀 홀란드 비.브이. | 사스-코로나바이러스에 대한 결합분자 및 그것의 용도 |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US8592368B2 (en) | 2003-12-19 | 2013-11-26 | University Of South Florida | JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection |
NZ550340A (en) * | 2004-03-17 | 2010-08-27 | Lars Michael Larsen | Prevention of retinopathy by inhibition of the visual cycle using a retinoid |
ES2426725T3 (es) | 2004-05-27 | 2013-10-24 | Crucell Holland B.V. | Método para identificar moléculas de unión que pueden neutralizar el virus de la rabia |
EP1765313A2 (en) | 2004-06-24 | 2007-03-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
WO2006019851A1 (en) * | 2004-07-23 | 2006-02-23 | Eli Lilly And Company | Methods for diagnosing and treating diabetic microvascular complications |
WO2006040322A1 (en) | 2004-10-12 | 2006-04-20 | Crucell Holland B.V. | Binding molecules for treatment and detection of cancer |
CA2582057C (en) | 2004-11-11 | 2015-08-11 | Crucell Holland B.V. | Compositions against sars-coronavirus and uses thereof |
WO2006068988A1 (en) * | 2004-12-20 | 2006-06-29 | Eli Lilly And Company | Combination therapy for vascular complications associated with hyperglycemia |
EP1877424A4 (en) * | 2005-04-11 | 2010-09-29 | Pharmagap Inc | INHIBITORS OF PROTEIN KINASES AND USES THEREOF |
EP1879921B1 (en) | 2005-05-12 | 2011-04-27 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
GEP20105124B (en) * | 2005-07-25 | 2010-11-25 | Array Biopharma Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
TW200803849A (en) | 2005-09-16 | 2008-01-16 | Schering Corp | Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor |
WO2007041195A2 (en) * | 2005-09-29 | 2007-04-12 | Janssen Pharmaceutica N.V. | Macroheterocylic compounds as kinase inhibitors |
KR20080056295A (ko) | 2005-10-11 | 2008-06-20 | 인터뮨, 인크. | C형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법 |
CA2645289A1 (en) * | 2006-03-10 | 2007-09-20 | Janssen Pharmaceutica, N.V. | Pyridine-containing macroheterocylic compounds as kinase inhibitors |
US8426355B2 (en) * | 2006-03-15 | 2013-04-23 | Theralogics, Inc. | Methods of treating muscular wasting diseases using NF-κB activation inhibitors |
US7960518B2 (en) | 2006-06-06 | 2011-06-14 | Crucell Holland B.V. | Human binding molecules having killing activity against enterococci and uses thereof |
DK2395018T3 (en) | 2006-06-06 | 2016-04-25 | Crucell Holland Bv | HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof |
RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
US8445437B2 (en) * | 2006-07-27 | 2013-05-21 | The Brigham And Women's Hospital, Inc. | Treatment and prevention of cardiovascular disease using mast cell stabilizers |
AU2007293662B2 (en) | 2006-09-07 | 2012-10-04 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof |
EP2455398B1 (en) | 2006-09-07 | 2015-11-18 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof |
EP2177523A1 (en) * | 2007-05-03 | 2010-04-21 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
AP2009005057A0 (en) * | 2007-05-10 | 2009-12-31 | Array Biopharma Inc | Novel peptide inhibitors of hepatitis c virus replication |
US8445435B2 (en) * | 2007-09-28 | 2013-05-21 | The Brigham And Women's Hospital, Inc. | Mast cell stabilizers in the treatment of obesity |
US20090130195A1 (en) | 2007-10-17 | 2009-05-21 | Mildred Acevedo-Duncan | Prostate carcinogenesis predictor |
US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
AP2010005416A0 (en) * | 2008-04-15 | 2010-10-31 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication. |
EP2181999A1 (en) | 2008-11-03 | 2010-05-05 | Zentiva, A.S. | Method of manufacturing ruboxistarin |
AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
CN102448986B (zh) | 2009-05-11 | 2015-11-25 | 克鲁塞尔荷兰公司 | 能中和流感病毒h3n2的人结合分子及其应用 |
JP2013505952A (ja) * | 2009-09-28 | 2013-02-21 | インターミューン・インコーポレーテッド | C型肝炎ウイルス複製の新しい大環状阻害剤 |
ES2385157B1 (es) * | 2010-02-25 | 2013-07-08 | Universidad Del País Vasco | Compuestos para el tratamiento de alzheimer. |
US8785648B1 (en) | 2010-08-10 | 2014-07-22 | The Regents Of The University Of California | PKC-epsilon inhibitors |
EP3180003B1 (en) | 2014-07-01 | 2022-01-12 | The Regents of the University of California | Pkc-epsilon inhibitors |
CN110300584A (zh) | 2016-12-19 | 2019-10-01 | 克罗马德姆公司 | 治疗色素沉着过度病症的方法 |
WO2019000224A1 (zh) * | 2017-06-27 | 2019-01-03 | 中国海洋大学 | 双吲哚马来酰亚胺衍生物及其制备方法和用途 |
US11590131B2 (en) | 2017-07-28 | 2023-02-28 | Applied Therapeutics, Inc. | Compositions and methods for treating galactosemia |
JP2023524504A (ja) | 2020-05-01 | 2023-06-12 | アプライド セラピューティクス, インコーポレイテッド | ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4785085A (en) * | 1986-11-21 | 1988-11-15 | Bristol-Myers Company | Rebeccamycin analogs |
US4808613A (en) * | 1986-11-21 | 1989-02-28 | Bristol-Myers Company | Rebeccamycin derivative containing pharmaceutical composition |
EP0303697B1 (en) * | 1987-03-09 | 1997-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance k-252 |
JPH07113027B2 (ja) * | 1987-12-24 | 1995-12-06 | 協和醗酵工業株式会社 | K−252誘導体 |
US5438050A (en) * | 1988-02-06 | 1995-08-01 | Godecke Aktiengesellschaft | Indolocarbazole derivatives, processes for their preparation and compositions containing them |
DE3803620A1 (de) * | 1988-02-06 | 1989-08-17 | Goedecke Ag | Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
SK278989B6 (sk) * | 1988-02-10 | 1998-05-06 | F. Hoffmann-La Roche Ag | Substituované pyroly, ich použitie na výrobu lieči |
MC2096A1 (fr) * | 1989-02-23 | 1991-02-15 | Hoffmann La Roche | Pyrroles substitues |
CA2015996C (en) * | 1989-05-05 | 2001-08-28 | Hartmut Osswald | Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals |
DE3914764A1 (de) * | 1989-05-05 | 1990-11-08 | Goedecke Ag | Maleinimid-derivate und deren verwendung als arzneimittel |
US5380746A (en) * | 1989-05-05 | 1995-01-10 | Goedecke Aktiengesellschaft | Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
DE3924538A1 (de) * | 1989-07-25 | 1991-01-31 | Goedecke Ag | Indolocarbazol und dessen verwendung |
DE3942296A1 (de) * | 1989-12-21 | 1991-06-27 | Goedecke Ag | Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung |
DE4005969A1 (de) * | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
DE4005970A1 (de) * | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
US5292747A (en) * | 1990-08-07 | 1994-03-08 | Hoffman-La Roche Inc. | Substituted pyrroles |
CA2046801C (en) * | 1990-08-07 | 2002-02-26 | Peter D. Davis | Substituted pyrroles |
CA2108146A1 (en) * | 1991-04-11 | 1992-10-12 | Stuart W. Mccombie | Anti-tumor and anti-psoriatic agents |
GB9123396D0 (en) * | 1991-11-04 | 1991-12-18 | Hoffmann La Roche | A process for the manufacture of substituted maleimides |
US5344926A (en) * | 1992-06-22 | 1994-09-06 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing staurosporine derivatives |
US5461146A (en) * | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
US5589472A (en) * | 1992-09-25 | 1996-12-31 | Vice; Susan F. | Diindolo compounds and pharmaceutical compositions containing them |
DE4243321A1 (de) * | 1992-12-21 | 1994-06-23 | Goedecke Ag | Aminosäurederivate von Heterocyclen als PKC-Inhibitoren |
PH30300A (en) * | 1993-05-07 | 1997-01-20 | Ciba Geigy Ag | Polycyclic compounds and processes for the preparation thereof |
AU678435B2 (en) * | 1993-05-10 | 1997-05-29 | F. Hoffmann-La Roche Ag | Substituted pyrroles |
IL111851A (en) * | 1993-12-07 | 1998-09-24 | Lilly Co Eli | Improved synthesis of bisindolylsimilides and process for its preparation |
BR9404831A (pt) * | 1993-12-07 | 1995-08-08 | Lilly Co Eli | Composto,formulação farmacêutica e processo de preparação de um composto |
US5481003A (en) * | 1994-06-22 | 1996-01-02 | Eli Lilly And Company | Protein kinase C inhibitors |
DE69600784T2 (de) * | 1995-11-20 | 1999-04-08 | Lilly Co Eli | Proteinkinase-C-Inhibitor |
-
1995
- 1995-03-30 US US08/413,735 patent/US5624949A/en not_active Expired - Fee Related
- 1995-06-01 US US08/457,000 patent/US5552396A/en not_active Expired - Lifetime
- 1995-06-01 US US08/457,657 patent/US5621098A/en not_active Expired - Fee Related
- 1995-06-01 US US08/457,060 patent/US5674862A/en not_active Expired - Lifetime
-
1996
- 1996-03-28 CA CA002216535A patent/CA2216535C/en not_active Expired - Fee Related
- 1996-03-28 MX MX9707431A patent/MX9707431A/es unknown
- 1996-03-28 EA EA199700280A patent/EA000598B1/ru not_active IP Right Cessation
- 1996-03-28 CZ CZ19973051A patent/CZ286301B6/cs not_active IP Right Cessation
- 1996-03-28 AU AU53249/96A patent/AU701988B2/en not_active Ceased
- 1996-03-28 HU HU9801250A patent/HUP9801250A3/hu unknown
- 1996-03-28 TR TR97/01073T patent/TR199701073T1/xx unknown
- 1996-03-28 WO PCT/US1996/004245 patent/WO1996030048A1/en active IP Right Grant
- 1996-03-28 NZ NZ305276A patent/NZ305276A/xx unknown
- 1996-03-28 PL PL96322584A patent/PL183600B1/pl unknown
- 1996-03-28 JP JP8529640A patent/JPH11507327A/ja not_active Withdrawn
- 1996-03-28 CN CN96194257A patent/CN1093767C/zh not_active Expired - Fee Related
- 1996-03-28 KR KR1019970706785A patent/KR100319945B1/ko not_active IP Right Cessation
- 1996-03-28 EP EP96302142A patent/EP0735038A1/en not_active Withdrawn
- 1996-05-06 US US08/643,710 patent/US5780461A/en not_active Expired - Fee Related
- 1996-05-06 US US08/646,708 patent/US5719175A/en not_active Expired - Fee Related
- 1996-05-06 US US08/646,703 patent/US5696108A/en not_active Expired - Fee Related
-
1997
- 1997-03-20 US US08/822,255 patent/US5739322A/en not_active Expired - Fee Related
- 1997-09-26 NO NO974453A patent/NO309271B1/no not_active IP Right Cessation
- 1997-11-14 US US08/971,115 patent/US5821365A/en not_active Expired - Fee Related
- 1997-11-14 US US08/970,891 patent/US6057440A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NO974453D0 (no) | 1997-09-26 |
PL322584A1 (en) | 1998-02-02 |
EA000598B1 (ru) | 1999-12-29 |
WO1996030048A1 (en) | 1996-10-03 |
CZ305197A3 (cs) | 1998-05-13 |
CA2216535C (en) | 2002-05-07 |
HUP9801250A2 (hu) | 1998-09-28 |
TR199701073T1 (xx) | 1998-02-21 |
CN1093767C (zh) | 2002-11-06 |
KR100319945B1 (ko) | 2002-03-08 |
HUP9801250A3 (en) | 1998-12-28 |
MX9707431A (es) | 1997-12-31 |
US5552396A (en) | 1996-09-03 |
US5821365A (en) | 1998-10-13 |
US5739322A (en) | 1998-04-14 |
EA199700280A1 (ru) | 1998-02-26 |
PL183600B1 (pl) | 2002-06-28 |
US5674862A (en) | 1997-10-07 |
CA2216535A1 (en) | 1996-10-03 |
NO309271B1 (no) | 2001-01-08 |
CN1185742A (zh) | 1998-06-24 |
NZ305276A (en) | 1999-02-25 |
US5624949A (en) | 1997-04-29 |
KR19980703380A (ko) | 1998-10-15 |
AU5324996A (en) | 1996-10-16 |
US5621098A (en) | 1997-04-15 |
JPH11507327A (ja) | 1999-06-29 |
AU701988B2 (en) | 1999-02-11 |
US5719175A (en) | 1998-02-17 |
CZ286301B6 (cs) | 2000-03-15 |
US5780461A (en) | 1998-07-14 |
US5696108A (en) | 1997-12-09 |
EP0735038A1 (en) | 1996-10-02 |
US6057440A (en) | 2000-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO974453L (no) | Proteinkinase C-hemmere | |
DK0776895T3 (da) | Proteinkinase C inhibitor | |
DE69435267D1 (de) | Proteinkinase C Inhibitoren | |
DE69627179D1 (de) | Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren | |
NO20002121D0 (no) | Benzotiazol-protein-tyrosin-kinaseinhibitorer | |
NO992336D0 (no) | Raf-kinase-inhibitorer | |
DE69323185T2 (de) | Proteinkinase c-inhibitor | |
IS4771A (is) | Interlevkín-1ß umbreytiensím tálmar | |
ATE216997T1 (de) | Zyklische gmp-spezifische phosphodiesteraseinhibitoren | |
PT858464E (pt) | Inibidores de trombina | |
DK0858452T3 (da) | Thiazolderivater som proteinkinase C-inhibitorer | |
DE69622983T2 (de) | Chip-spule | |
DE19680964T1 (de) | Speichertestgerät | |
ATE387448T1 (de) | 4,5-pyrazinoxindole als proteinkinasehemmer | |
BR9609671A (pt) | Amino uracilas substituídas | |
DE69614075D1 (de) | Inhibitoren von Mehrfachresistenzen | |
DE69734817D1 (de) | Neuartige amp-aktivierte proteinkinase | |
PT863916E (pt) | Tripeptidos de polifluoroalquil triptofano inibidores de trombina | |
ZA949611B (en) | Protein kinase C inhibitors | |
NO981435D0 (no) | Skriver | |
BR9610514A (pt) | Inibidores cicloantihelmínticos | |
ITMI930345A0 (it) | N-acil-peptidi inibitori delle protein-chinasi | |
KR960033453U (ko) | 건강음료 보약탕기 | |
KR970703937A (ko) | 금속단백질 분해효소 억제제(Metallproteinase inhibitors) | |
FI950022A0 (fi) | Eosinofiiliset kemotaksiainhibiittorit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN SEPTEMBER 2003 |